{"gene":"AGPAT2","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2002,"finding":"AGPAT2 encodes a 1-acylglycerol-3-phosphate O-acyltransferase that catalyzes the acylation of lysophosphatidic acid (LPA) to form phosphatidic acid (PA), a key intermediate in the biosynthesis of triacylglycerol and glycerophospholipids; loss-of-function mutations cause congenital generalized lipodystrophy.","method":"Mutation identification in human patients combined with enzymatic function annotation of the AGPAT2 protein","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity of AGPAT2 established biochemically, causative mutations identified in multiple independent pedigrees, replicated extensively","pmids":["11967537"],"is_preprint":false},{"year":2011,"finding":"Human AGPAT2 and AGPAT1 show similar in vitro substrate specificities for LPA and acyl-CoA; both co-localize to the endoplasmic reticulum when co-expressed; protein homology modeling with GPAT1 reveals similar tertiary structure consistent with substrate specificity.","method":"In vitro enzymatic assays with LPA and acyl-CoA substrates, co-localization by fluorescence microscopy, protein homology modeling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assay with substrate specificity profiling, structural modeling, direct localization by co-expression imaging, single lab with multiple orthogonal methods","pmids":["21873652"],"is_preprint":false},{"year":2011,"finding":"Restoring AGPAT2 activity specifically in the liver by adenoviral overexpression of AGPAT1 or AGPAT2 in Agpat2-/- mice failed to ameliorate hepatic steatosis, indicating that liver-specific AGPAT activity is not the primary driver of hepatic fat accumulation in lipodystrophy.","method":"Adenoviral gene delivery to liver of Agpat2-/- mice followed by measurement of liver triglycerides","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean in vivo genetic rescue experiment, single lab, negative finding is mechanistically informative","pmids":["21873652"],"is_preprint":false},{"year":2009,"finding":"In Agpat2-/- mice, hepatic de novo fatty acid biosynthesis is increased ~4-fold and monoacylglycerol acyltransferase isoform 1 (MOGAT1) mRNA and protein are markedly upregulated, indicating activation of an alternative monoacylglycerol pathway for triglyceride biosynthesis to compensate for AGPAT2 deficiency.","method":"Agpat2 knockout mouse model; de novo lipogenesis rates measured; mRNA and protein analysis of MOGAT1; fat-free diet intervention","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (metabolic flux, gene/protein expression, dietary intervention) in a clean KO model, single lab with rigorous controls","pmids":["19187773"],"is_preprint":false},{"year":2015,"finding":"Seipin oligomers (dodecamers) can directly interact with AGPAT2 during adipogenesis, and a single seipin complex can simultaneously bind both AGPAT2 and lipin 1, physically scaffolding these two sequential enzymes of the PA biosynthesis pathway; stabilizing the seipin-AGPAT2 interaction increases nuclear accumulation of PPARγ.","method":"Co-immunoprecipitation, immunofluorescence, atomic force microscopy (AFM) to determine direct protein-protein interaction and molecular architecture","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct interaction confirmed by AFM reconstitution plus reciprocal Co-IP and functional consequence (PPARγ nuclear accumulation), single lab with multiple orthogonal methods","pmids":["25737955"],"is_preprint":false},{"year":2012,"finding":"AGPAT2 regulates adipogenesis by modulating levels of phosphatidic acid, lysophosphatidic acid, phosphatidylinositol species, and the PPARγ inhibitor cyclic phosphatidic acid; loss of AGPAT2 activity reduces Akt activation, and constitutively active Akt partially restores lipogenesis, placing AGPAT2 upstream of PI3K/Akt and PPARγ pathways in early adipogenesis.","method":"Knockdown and overexpression of AGPAT2 in 3T3-L1 and patient-derived MDMCs; lipidomics; retroviral rescue; constitutively active Akt rescue; PPARγ agonist rescue","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including lipidomics, genetic epistasis via constitutively active Akt, and pharmacological rescue, single lab","pmids":["22872237"],"is_preprint":false},{"year":2014,"finding":"Specific molecular species of phosphatidic acid (PA C16:0/18:1 and C18:1/20:4) generated in the absence of AGPAT2 enhance hepatic glucose production (HGP) in primary hepatocytes by upregulating gluconeogenic enzymes glucose-6-phosphatase and PEPCK; this PA-driven gluconeogenesis is suppressed by insulin in wild-type but not Agpat2-/- hepatocytes, establishing PA as a driver of hepatic insulin resistance.","method":"Primary hepatocyte assays with exogenous PA species; measurement of glucose production; diacylglycerol kinase and phospholipase D activity assays in Agpat2-/- liver; insulin suppression experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution with defined lipid species, biochemical assays of upstream enzymes, and functional insulin-signaling readout in KO vs WT cells, single lab, multiple methods","pmids":["24425876"],"is_preprint":false},{"year":2021,"finding":"AGPAT2 directly interacts with CDP-diacylglycerol synthases (CDS1 and CDS2), forming functional complexes that promote flux of PA into the CDP-DAG phospholipid synthesis pathway; AGPAT2 deficiency destabilizes CDS proteins and reduces CDS activity, paradoxically increasing PA levels despite AGPAT2 producing PA.","method":"Co-immunoprecipitation, lipidomics, CDS activity assays in cell lines and mouse liver, knockout models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reciprocal Co-IP demonstrating direct interaction, enzyme activity assays, lipidomics, and KO models in two systems (cells and mouse liver), single lab with multiple orthogonal methods","pmids":["34824276"],"is_preprint":false},{"year":2016,"finding":"AGPAT2 deficiency causes postnatal loss of both white and brown adipose tissue through adipocyte death and local inflammation during the first postnatal week; Agpat2-/- adipocytes are virtually devoid of caveolae, have abnormal mitochondria and lipid droplets, and show 3-fold elevated phosphatidic acid in phospholipid composition; PPARγ overexpression increases differentiation but does not rescue morphological abnormalities or cell death.","method":"Light and electron microscopy of adipose tissue, phospholipid profiling by ESI-MS/MS, PPARγ overexpression rescue in MEFs, immunoblot and qPCR","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ultrastructural analysis combined with lipidomics, genetic rescue experiment, and mRNA/protein analysis in both in vivo and in vitro systems, single lab with multiple orthogonal methods","pmids":["27408775"],"is_preprint":false},{"year":2018,"finding":"AGPAT2 gene expression is directly regulated by HIF-1 transcription factor; HIF-1α binds a specific HRE in the AGPAT2 promoter (confirmed by ChIP), and mutation of this HRE abolishes hypoxic activation; AGPAT2 knockdown reduces lipid droplet accumulation and cell viability under hypoxia and increases sensitivity to etoposide.","method":"siRNA knockdown of HIF-1α; reporter gene assays with AGPAT2 promoter-HRE constructs; chromatin immunoprecipitation (ChIP); HRE mutagenesis; lipid droplet quantification; cell viability assays","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP confirming direct TF binding, HRE mutagenesis abolishing activation, functional knockdown phenotype, multiple orthogonal methods in single lab","pmids":["29908837"],"is_preprint":false},{"year":2020,"finding":"Seipin and GPAT3 associate via direct interaction, and seipin can simultaneously bind GPAT3 and AGPAT2, suggesting a trimeric complex that co-ordinates sequential steps of the glycerophospholipid pathway; inhibition of AGPAT2 or GPAT3 individually impairs early adipocyte differentiation markers.","method":"Co-immunoprecipitation, siRNA knockdown of seipin/AGPAT2/GPAT3, adipogenesis assays in cultured cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP showing direct interaction and functional KD effects on adipogenesis, but trimeric complex inferred rather than directly demonstrated, single lab","pmids":["32094408"],"is_preprint":false},{"year":2012,"finding":"The p.Cys48Arg and p.Leu228Pro AGPAT2 mutations result in significantly reduced protein levels despite normal mRNA levels (post-translational destabilization); these mutants fail to rescue adipogenesis in AGPAT2-deficient preadipocytes, whereas wild-type AGPAT2 partially rescues differentiation.","method":"Expression of mutant vs wild-type AGPAT2 in AGPAT2-deficient preadipocytes; mRNA and protein quantification; adipogenesis rescue assay","journal":"JIMD reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — protein vs mRNA discordance established by direct measurement, functional rescue experiment, single lab with two orthogonal readouts","pmids":["23430550"],"is_preprint":false},{"year":2018,"finding":"A double-mutant AGPAT2 protein (V67M;V167A) is enzymatically inactive as measured by in vitro mass spectrometry-based activity assay, and is associated with partial lipodystrophy when present as a single complex allele.","method":"In vitro enzymatic activity assay with mass spectrometry readout; whole genome sequencing for allele identification","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro enzymatic assay is Tier 1, but single patient case study with single lab, no independent replication","pmids":["30319454"],"is_preprint":false},{"year":2023,"finding":"Adipose-tissue-specific re-expression of human AGPAT2 in Agpat2-null mice under doxycycline regulation results in partial regeneration of white and brown adipose tissue with molecular adipocyte signatures and leptin secretion; turning off AGPAT2 expression causes total loss of regenerated adipose tissue, establishing AGPAT2 as essential for adipocyte differentiation in vivo.","method":"Doxycycline-inducible adipose-specific transgene expression in Agpat2-null mice; adipose tissue mass, histology, leptin secretion measurement; ex vivo differentiation of stromal vascular fraction cells","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reversible genetic rescue with dox on/off demonstrating causal role of AGPAT2 in adipocyte differentiation, multiple functional readouts, single lab","pmids":["37752957"],"is_preprint":false},{"year":2025,"finding":"AGPAT2-generated phosphatidic acid (PA) drives ER tubulation by directly interacting with and supplying PA to the dynamin-related GTPase DRP1, which subsequently tubulates the ER independently of GTP hydrolysis and oligomerization; reduction of PA by ectopic LIPIN1 expression converts ER tubules into sheets, establishing AGPAT2 as a critical regulator of ER morphogenesis.","method":"Gene knockout, 3D structural analysis by FIB-SEM, super-resolution microscopy, lipidomics, AlphaFold structural modeling, in vitro reconstitution of ER tubulation, in vitro AGPAT2 activity assay, LIPIN1 ectopic expression","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of ER tubulation, direct enzymatic assay, multiple structural methods (FIB-SEM, super-resolution), lipidomics, and genetic epistasis all in single study; multiple orthogonal methods with rigorous controls","pmids":["41387688"],"is_preprint":false},{"year":2026,"finding":"AGPAT2 localizes to nuclear pore complexes (NPCs) where it is bound and inhibited by Dop1a under mTOR signaling control to regulate phospholipid abundance in nuclear membranes; when LPA is limiting, Dop1a rapidly translocates to NPCs and suppresses AGPAT2-mediated PA synthesis, preventing formation of nuclear lipid droplets.","method":"Localization studies of AGPAT2 at NPCs, Dop1a knockout and rescue, mTOR signaling perturbation, nuclear lipid droplet quantification, nuclear membrane phospholipid measurement","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct binding and NPC localization demonstrated functionally, but single lab and limited replication; mechanistic detail of Dop1a-AGPAT2 interaction at NPCs is novel","pmids":["42164854"],"is_preprint":false},{"year":2026,"finding":"AGPAT2 inhibitor (LPAAT-β inhibitor CT-32615) triggers G2/M cell cycle arrest via downregulation of cdc25c and cdc2, and induces necrotic cell death (without caspase/PARP cleavage) even in bortezomib-resistant cells.","method":"Pharmacological inhibition of LPAAT-β/AGPAT2 with CT-32615; cell cycle analysis; caspase/PARP cleavage assays; cell viability assays in resistant cell lines","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — pharmacological inhibition with defined cell-cycle and death mechanism readouts, but relies on inhibitor specificity assumption; single lab with multiple phenotypic readouts","pmids":["15735676"],"is_preprint":false},{"year":2021,"finding":"Decreased caveolae in Agpat2-/- adipocytes are not associated with changes in plasma membrane cholesterol or sphingolipid levels, nor with changes in caveolin-1 or cavin-1 protein levels; however, increased plasma membrane phosphatidylserine is detected in Agpat2-/- adipocytes at day 10 of differentiation, suggesting a possible role for this lipid in caveolae reduction.","method":"Plasma membrane purification by ultracentrifugation; sterol, sphingolipid, and phospholipid lipidomics; caveolae quantification by electron microscopy; immunoblot for caveolin-1 and cavin-1","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comprehensive lipidomics with subcellular fractionation and protein analysis, negative findings are mechanistically informative, single lab","pmids":["33989739"],"is_preprint":false}],"current_model":"AGPAT2 is an endoplasmic reticulum-localized (and nuclear pore complex-associated) lysophosphatidic acid acyltransferase that catalyzes the conversion of LPA to phosphatidic acid (PA) in the glycerol-3-phosphate pathway; the PA it generates drives ER tubulation via direct interaction with DRP1, channels into the CDP-DAG phospholipid synthesis pathway through direct interaction with CDS1/2, and is an essential regulator of adipocyte differentiation acting upstream of PI3K/Akt and PPARγ signaling; seipin scaffolds AGPAT2 together with lipin 1 in a multiprotein complex at the ER to coordinate sequential PA metabolism steps during adipogenesis, while HIF-1α directly transactivates AGPAT2 expression under hypoxia to promote lipid droplet accumulation and cell survival."},"narrative":{"mechanistic_narrative":"AGPAT2 is an endoplasmic reticulum-localized 1-acylglycerol-3-phosphate O-acyltransferase that acylates lysophosphatidic acid (LPA) to phosphatidic acid (PA), a central intermediate for triacylglycerol and glycerophospholipid biosynthesis, and its loss-of-function mutations cause congenital generalized lipodystrophy [PMID:11967537, PMID:21873652]. The PA pool generated by AGPAT2 serves multiple downstream fates: it is channeled into the CDP-DAG phospholipid synthesis pathway through direct interaction with the CDP-diacylglycerol synthases CDS1/CDS2, whose stability and activity depend on AGPAT2 [PMID:34824276], and it drives ER tubulation by supplying PA to the dynamin-related GTPase DRP1 to remodel ER membrane morphology [PMID:41387688]. AGPAT2 is an essential regulator of adipocyte differentiation, acting upstream of PI3K/Akt and PPARγ signaling by tuning levels of PA, LPA, phosphatidylinositol species, and the PPARγ inhibitor cyclic PA [PMID:22872237], and its activity is genetically required for adipose tissue formation and maintenance in vivo [PMID:37752957]. At the ER, seipin oligomers physically scaffold AGPAT2 together with lipin 1 to coordinate sequential PA metabolism during adipogenesis [PMID:25737955]. Transcriptionally, HIF-1α directly binds an HRE in the AGPAT2 promoter to induce its expression under hypoxia, promoting lipid droplet accumulation and cell survival [PMID:29908837]. Misregulation of AGPAT2-derived PA has systemic metabolic consequences, including PA-species-driven hepatic glucose production and insulin resistance [PMID:24425876].","teleology":[{"year":2002,"claim":"Established the molecular identity and clinical relevance of AGPAT2 by linking its acyltransferase activity to a human disease, answering what the gene does and why its loss matters.","evidence":"Mutation identification in lipodystrophy patients combined with enzymatic function annotation","pmids":["11967537"],"confidence":"High","gaps":["Did not resolve subcellular site of catalysis","Did not define which downstream PA pools account for the disease phenotype"]},{"year":2009,"claim":"Showed how cells compensate for AGPAT2 loss, revealing activation of an alternative MOGAT1-dependent monoacylglycerol pathway and elevated de novo lipogenesis as a route to triglyceride synthesis.","evidence":"Agpat2 knockout mouse with metabolic flux, gene/protein expression, and dietary intervention","pmids":["19187773"],"confidence":"High","gaps":["Did not establish whether compensation occurs in adipose or only liver","Did not link compensatory pathway to lipodystrophy progression"]},{"year":2011,"claim":"Defined the biochemical substrate specificity and ER localization of AGPAT2 and showed, via liver-specific rescue failure, that hepatic AGPAT activity is not the primary driver of lipodystrophic steatosis.","evidence":"In vitro acyltransferase assays, co-localization imaging, homology modeling, and adenoviral liver rescue in knockout mice","pmids":["21873652"],"confidence":"High","gaps":["Did not identify the tissue where AGPAT2 activity is essential","No experimental structure of AGPAT2"]},{"year":2012,"claim":"Placed AGPAT2 upstream of PI3K/Akt and PPARγ in adipogenesis by showing that its lipid products control these signaling pathways, and identified post-translational destabilization as a disease mechanism for specific mutants.","evidence":"Knockdown/overexpression in 3T3-L1 and patient cells, lipidomics, Akt and PPARγ rescue; mutant protein/mRNA quantification and rescue assays","pmids":["22872237","23430550"],"confidence":"High","gaps":["Did not define which PA/LPA species mediate each signaling step","Mechanism connecting lipid changes to Akt activation not resolved"]},{"year":2014,"claim":"Connected AGPAT2-related lipid dysregulation to systemic insulin resistance by showing that specific PA species accumulating in its absence drive hepatic glucose production resistant to insulin suppression.","evidence":"Primary hepatocyte assays with defined PA species, gluconeogenic enzyme measurement, and insulin suppression in KO vs WT","pmids":["24425876"],"confidence":"High","gaps":["Did not identify the PA receptor/sensor driving gluconeogenesis","Did not separate liver-autonomous from systemic effects"]},{"year":2015,"claim":"Revealed how AGPAT2 is spatially organized for adipogenesis, demonstrating that seipin scaffolds AGPAT2 and lipin 1 into a complex that coordinates sequential PA metabolism and promotes PPARγ nuclear accumulation.","evidence":"Co-immunoprecipitation, immunofluorescence, and atomic force microscopy","pmids":["25737955"],"confidence":"High","gaps":["Stoichiometry of the in vivo complex not resolved","Did not show PA channeling within the complex directly"]},{"year":2016,"claim":"Characterized the cellular and ultrastructural basis of adipose loss in AGPAT2 deficiency, showing postnatal adipocyte death, absent caveolae, abnormal organelles, and elevated PA that PPARγ overexpression cannot rescue.","evidence":"Electron microscopy, phospholipid profiling by ESI-MS/MS, and PPARγ rescue in MEFs","pmids":["27408775"],"confidence":"High","gaps":["Mechanism linking PA elevation to adipocyte death unresolved","Cause of caveolae loss not identified"]},{"year":2018,"claim":"Identified hypoxia-driven transcriptional control of AGPAT2 by HIF-1α and tied this to lipid droplet accumulation and survival, expanding AGPAT2's role beyond adipogenesis into stress responses.","evidence":"HIF-1α knockdown, AGPAT2 promoter-HRE reporters, ChIP, HRE mutagenesis, lipid droplet and viability assays","pmids":["29908837"],"confidence":"High","gaps":["Did not establish tissue contexts where this axis operates","Did not link HIF-driven AGPAT2 to tumor lipid metabolism in vivo"]},{"year":2018,"claim":"Provided direct enzymatic evidence that compound missense mutations abolish AGPAT2 catalytic activity and associate with partial lipodystrophy, refining genotype-function correlation.","evidence":"In vitro mass spectrometry activity assay and whole genome sequencing in a patient case","pmids":["30319454"],"confidence":"Medium","gaps":["Single patient case without independent replication","Did not separate contributions of each mutation"]},{"year":2020,"claim":"Extended the seipin scaffolding model upstream by showing seipin can also bind GPAT3 and simultaneously engage AGPAT2, implying a trimeric platform for sequential glycerophospholipid synthesis in adipogenesis.","evidence":"Co-immunoprecipitation, siRNA knockdown, and adipogenesis assays in cultured cells","pmids":["32094408"],"confidence":"Medium","gaps":["Trimeric complex inferred rather than directly demonstrated","Stoichiometry and assembly order not resolved"]},{"year":2021,"claim":"Resolved the paradox of PA accumulation in AGPAT2 deficiency by showing AGPAT2 directly binds and stabilizes CDS1/CDS2 to channel PA into the CDP-DAG pathway, so its loss collapses downstream PA consumption.","evidence":"Reciprocal Co-IP, lipidomics, CDS activity assays, and knockout models in cells and mouse liver","pmids":["34824276"],"confidence":"High","gaps":["Structural basis of AGPAT2-CDS interaction not determined","Did not quantify substrate channeling kinetics"]},{"year":2021,"claim":"Dissected the caveolae defect in AGPAT2-null adipocytes, excluding cholesterol, sphingolipid, and caveolin/cavin protein changes and implicating elevated plasma membrane phosphatidylserine.","evidence":"Plasma membrane fractionation, lipidomics, electron microscopy, and immunoblotting","pmids":["33989739"],"confidence":"Medium","gaps":["Causal role of phosphatidylserine in caveolae loss not proven","Did not connect caveolae loss to adipocyte function"]},{"year":2023,"claim":"Established AGPAT2 as causally required for adipocyte differentiation in vivo through reversible adipose-specific re-expression that regenerates adipose tissue and is lost when expression is switched off.","evidence":"Doxycycline-inducible adipose-specific transgene in Agpat2-null mice with histology, leptin, and ex vivo differentiation","pmids":["37752957"],"confidence":"High","gaps":["Did not identify the minimal AGPAT2-dependent lipid signal for differentiation","Partial regeneration mechanism not fully defined"]},{"year":2025,"claim":"Uncovered a structural role for AGPAT2-generated PA in organelle morphogenesis, showing PA is supplied to DRP1 to drive ER tubulation independently of DRP1 GTP hydrolysis, with PA reduction converting tubules into sheets.","evidence":"Knockout, FIB-SEM, super-resolution microscopy, lipidomics, AlphaFold modeling, in vitro ER tubulation reconstitution and activity assays, LIPIN1 expression","pmids":["41387688"],"confidence":"High","gaps":["Did not define how local PA pools are spatially restricted at ER tubules","Physiological consequences of altered ER morphology in lipodystrophy not assessed"]},{"year":2026,"claim":"Revealed a nuclear pore complex pool of AGPAT2 under mTOR/Dop1a control that gates nuclear membrane phospholipid synthesis and prevents nuclear lipid droplet formation when LPA is limiting.","evidence":"NPC localization studies, Dop1a knockout/rescue, mTOR perturbation, and nuclear lipid droplet and phospholipid measurements","pmids":["42164854"],"confidence":"Medium","gaps":["Single lab with limited replication of NPC localization","Molecular details of Dop1a-AGPAT2 inhibition not structurally defined"]},{"year":2026,"claim":"Demonstrated that pharmacological AGPAT2/LPAAT-β inhibition imposes G2/M arrest and caspase-independent necrotic death, including in bortezomib-resistant cells, indicating a role in cell cycle and survival exploitable therapeutically.","evidence":"CT-32615 inhibition with cell cycle analysis, caspase/PARP assays, and viability in resistant lines","pmids":["15735676"],"confidence":"Medium","gaps":["Relies on inhibitor specificity for AGPAT2","Mechanism linking AGPAT2 activity to cdc25c/cdc2 downregulation not established"]},{"year":null,"claim":"How AGPAT2-generated PA is spatially partitioned among its distinct fates — CDS-mediated phospholipid synthesis, DRP1-driven ER tubulation, signaling pools regulating adipogenesis, and nuclear membrane biogenesis — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental structure of AGPAT2 or its protein complexes","No mechanism explaining selective channeling of PA into competing downstream pathways","Tissue-specific regulation of the distinct AGPAT2 functions undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,12,14]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,14]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,6,7]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,13]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[14]}],"complexes":["seipin–AGPAT2–lipin 1 scaffold complex","AGPAT2–CDS1/CDS2 complex"],"partners":["BSCL2","LPIN1","CDS1","CDS2","GPAT3","DRP1","DOP1A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15120","full_name":"1-acyl-sn-glycerol-3-phosphate acyltransferase beta","aliases":["1-acylglycerol-3-phosphate O-acyltransferase 2","1-AGP acyltransferase 2","1-AGPAT 2","Lysophosphatidic acid acyltransferase beta","LPAAT-beta"],"length_aa":278,"mass_kda":30.9,"function":"Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/O15120/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AGPAT2","classification":"Not Classified","n_dependent_lines":22,"n_total_lines":1208,"dependency_fraction":0.018211920529801324},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000169692","cell_line_id":"CID000328","localizations":[{"compartment":"er","grade":3},{"compartment":"vesicles","grade":2}],"interactors":[],"url":"https://opencell.sf.czbiohub.org/target/CID000328","total_profiled":1310},"omim":[{"mim_id":"612526","title":"LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3","url":"https://www.omim.org/entry/612526"},{"mim_id":"608612","title":"MANDIBULOACRAL DYSPLASIA WITH TYPE B LIPODYSTROPHY; MADB","url":"https://www.omim.org/entry/608612"},{"mim_id":"608594","title":"LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1","url":"https://www.omim.org/entry/608594"},{"mim_id":"606721","title":"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 7; FPLD7","url":"https://www.omim.org/entry/606721"},{"mim_id":"606158","title":"BSCL2 GENE; BSCL2","url":"https://www.omim.org/entry/606158"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":348.8},{"tissue":"liver","ntpm":426.9}],"url":"https://www.proteinatlas.org/search/AGPAT2"},"hgnc":{"alias_symbol":["LPAAT-beta","LPLAT2"],"prev_symbol":["BSCL"]},"alphafold":{"accession":"O15120","domains":[{"cath_id":"-","chopping":"22-262","consensus_level":"high","plddt":95.249,"start":22,"end":262}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15120","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15120-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15120-F1-predicted_aligned_error_v6.png","plddt_mean":91.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AGPAT2","jax_strain_url":"https://www.jax.org/strain/search?query=AGPAT2"},"sequence":{"accession":"O15120","fasta_url":"https://rest.uniprot.org/uniprotkb/O15120.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15120/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15120"}},"corpus_meta":[{"pmid":"11967537","id":"PMC_11967537","title":"AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11967537","citation_count":395,"is_preprint":false},{"pmid":"19187773","id":"PMC_19187773","title":"Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy.","date":"2009","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19187773","citation_count":187,"is_preprint":false},{"pmid":"14602785","id":"PMC_14602785","title":"Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14602785","citation_count":114,"is_preprint":false},{"pmid":"25737955","id":"PMC_25737955","title":"Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis.","date":"2015","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25737955","citation_count":73,"is_preprint":false},{"pmid":"21873652","id":"PMC_21873652","title":"Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21873652","citation_count":72,"is_preprint":false},{"pmid":"29908837","id":"PMC_29908837","title":"Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia.","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29908837","citation_count":69,"is_preprint":false},{"pmid":"12765973","id":"PMC_12765973","title":"Prevalence of mutations in AGPAT2 among human lipodystrophies.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12765973","citation_count":66,"is_preprint":false},{"pmid":"15181077","id":"PMC_15181077","title":"Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15181077","citation_count":50,"is_preprint":false},{"pmid":"22872237","id":"PMC_22872237","title":"Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations.","date":"2012","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/22872237","citation_count":50,"is_preprint":false},{"pmid":"24293639","id":"PMC_24293639","title":"Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24293639","citation_count":46,"is_preprint":false},{"pmid":"15735676","id":"PMC_15735676","title":"Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15735676","citation_count":41,"is_preprint":false},{"pmid":"34824276","id":"PMC_34824276","title":"AGPAT2 interaction with CDP-diacylglycerol synthases promotes the flux of fatty acids through the CDP-diacylglycerol pathway.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34824276","citation_count":38,"is_preprint":false},{"pmid":"27408775","id":"PMC_27408775","title":"AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue.","date":"2016","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27408775","citation_count":38,"is_preprint":false},{"pmid":"19226263","id":"PMC_19226263","title":"Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome.","date":"2009","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19226263","citation_count":36,"is_preprint":false},{"pmid":"14715872","id":"PMC_14715872","title":"Mutations in the seipin and AGPAT2 genes clustering in consanguineous families with Berardinelli-Seip congenital lipodystrophy from two separate geographical regions of Brazil.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14715872","citation_count":31,"is_preprint":false},{"pmid":"21051554","id":"PMC_21051554","title":"Pathology of congenital generalized lipodystrophy in Agpat2-/- mice.","date":"2010","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21051554","citation_count":28,"is_preprint":false},{"pmid":"32094408","id":"PMC_32094408","title":"Oligomers of the lipodystrophy protein seipin may co-ordinate GPAT3 and AGPAT2 enzymes to facilitate adipocyte differentiation.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32094408","citation_count":24,"is_preprint":false},{"pmid":"26880786","id":"PMC_26880786","title":"Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice.","date":"2016","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26880786","citation_count":22,"is_preprint":false},{"pmid":"32117065","id":"PMC_32117065","title":"Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32117065","citation_count":22,"is_preprint":false},{"pmid":"16435205","id":"PMC_16435205","title":"Phenotypic heterogeneity in biochemical parameters correlates with mutations in AGPAT2 or Seipin genes among Berardinelli-Seip congenital lipodystrophy patients.","date":"2005","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/16435205","citation_count":22,"is_preprint":false},{"pmid":"26417690","id":"PMC_26417690","title":"AGPAT2 deficiency impairs adipogenic differentiation in primary cultured preadipocytes in a non-autophagy or apoptosis dependent mechanism.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26417690","citation_count":20,"is_preprint":false},{"pmid":"24425876","id":"PMC_24425876","title":"Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24425876","citation_count":19,"is_preprint":false},{"pmid":"24498038","id":"PMC_24498038","title":"Divergent metabolic phenotype between two sisters with congenital generalized lipodystrophy due to double AGPAT2 homozygous mutations. a clinical, genetic and in silico study.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24498038","citation_count":16,"is_preprint":false},{"pmid":"22902344","id":"PMC_22902344","title":"Identification of a novel nonsense mutation and a missense substitution in the AGPAT2 gene causing congenital generalized lipodystrophy type 1.","date":"2012","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22902344","citation_count":13,"is_preprint":false},{"pmid":"23430550","id":"PMC_23430550","title":"Identification and Characterisation of a Novel Pathogenic Mutation in the Human Lipodystrophy Gene AGPAT2 : C48R: A Novel Mutation in AGPAT2.","date":"2012","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/23430550","citation_count":11,"is_preprint":false},{"pmid":"30520265","id":"PMC_30520265","title":"Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2.","date":"2018","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/30520265","citation_count":10,"is_preprint":false},{"pmid":"30319454","id":"PMC_30319454","title":"A Single Complex Agpat2 Allele in a Patient With Partial Lipodystrophy.","date":"2018","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30319454","citation_count":8,"is_preprint":false},{"pmid":"30266686","id":"PMC_30266686","title":"Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants.","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30266686","citation_count":8,"is_preprint":false},{"pmid":"29264548","id":"PMC_29264548","title":"Activation of Sphingolipid Pathway in the Livers of Lipodystrophic Agpat2 Mice.","date":"2017","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/29264548","citation_count":7,"is_preprint":false},{"pmid":"32280377","id":"PMC_32280377","title":"Leu124Serfs*26, a novel AGPAT2 mutation in congenital generalized lipodystrophy with early cardiovascular complications.","date":"2020","source":"Diabetology & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/32280377","citation_count":7,"is_preprint":false},{"pmid":"33989739","id":"PMC_33989739","title":"Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis.","date":"2021","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33989739","citation_count":7,"is_preprint":false},{"pmid":"21744063","id":"PMC_21744063","title":"Description of an AGPAT2 pathologic allelic variant in a 54-year-old Caucasian woman with Berardinelli-Seip syndrome.","date":"2011","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/21744063","citation_count":7,"is_preprint":false},{"pmid":"37591406","id":"PMC_37591406","title":"Lipodystrophic gene Agpat2 deficiency aggravates hyperlipidemia and atherosclerosis in Ldlr-/- mice.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37591406","citation_count":5,"is_preprint":false},{"pmid":"37752957","id":"PMC_37752957","title":"Regulated adipose tissue-specific expression of human AGPAT2 in lipodystrophic Agpat2-null mice results in regeneration of adipose tissue.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37752957","citation_count":5,"is_preprint":false},{"pmid":"36978948","id":"PMC_36978948","title":"Transcriptional Inhibition of AGPAT2 Induces Abnormal Lipid Metabolism and Oxidative Stress in the Liver of Nile Tilapia Oreochromis niloticus.","date":"2023","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36978948","citation_count":5,"is_preprint":false},{"pmid":"30563316","id":"PMC_30563316","title":"A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2 Splicesite Mutation and Concomitant Development of Non-diabetic Polyneuropathy.","date":"2018","source":"Journal of clinical research in pediatric endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30563316","citation_count":5,"is_preprint":false},{"pmid":"23337016","id":"PMC_23337016","title":"AGPAT2 gene mutation in a child with Berardinelli-Seip congenital lipodystrophy syndrome.","date":"2013","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/23337016","citation_count":5,"is_preprint":false},{"pmid":"40508223","id":"PMC_40508223","title":"The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40508223","citation_count":3,"is_preprint":false},{"pmid":"38274405","id":"PMC_38274405","title":"Adipose-specific overexpression of human AGPAT2 in mice causes increased adiposity and mild hepatic dysfunction.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38274405","citation_count":3,"is_preprint":false},{"pmid":"38623324","id":"PMC_38623324","title":"Regulated regeneration of adipose tissue in lipodystrophic Agpat2-null mice partially ameliorates hepatic steatosis.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38623324","citation_count":2,"is_preprint":false},{"pmid":"41387688","id":"PMC_41387688","title":"AGPAT2 acts at the crossroads of lipid biosynthesis and DRP1-mediated ER morphogenesis.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41387688","citation_count":1,"is_preprint":false},{"pmid":"38369771","id":"PMC_38369771","title":"LncRNA ENSGALG00000021686 regulates fat metabolism in chicken hepatocytes via miR-146b/AGPAT2 pathway.","date":"2024","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38369771","citation_count":1,"is_preprint":false},{"pmid":"40212223","id":"PMC_40212223","title":"A case of familial hypertriglyceridemia associated with a novel heterozygous AGPAT2 mutation.","date":"2025","source":"Annals of medicine and surgery (2012)","url":"https://pubmed.ncbi.nlm.nih.gov/40212223","citation_count":0,"is_preprint":false},{"pmid":"42164854","id":"PMC_42164854","title":"The mTOR-Dop1a-Agpat2 axis regulates nuclear phospholipid homeostasis.","date":"2026","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/42164854","citation_count":0,"is_preprint":false},{"pmid":"32924125","id":"PMC_32924125","title":"[Identification of a novel AGPAT2 variant in a Chinese patient with congenital generalized lipodystrophy type 1].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32924125","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.21.677575","title":"Insect-derived long non-coding RNAs function as epigenetic effectors to reprogram plant immunity","date":"2025-09-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.21.677575","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":25119,"output_tokens":4867,"usd":0.074181,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13200,"output_tokens":5056,"usd":0.0962,"stage2_stop_reason":"end_turn"},"total_usd":0.170381,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"AGPAT2 encodes a 1-acylglycerol-3-phosphate O-acyltransferase that catalyzes the acylation of lysophosphatidic acid (LPA) to form phosphatidic acid (PA), a key intermediate in the biosynthesis of triacylglycerol and glycerophospholipids; loss-of-function mutations cause congenital generalized lipodystrophy.\",\n      \"method\": \"Mutation identification in human patients combined with enzymatic function annotation of the AGPAT2 protein\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity of AGPAT2 established biochemically, causative mutations identified in multiple independent pedigrees, replicated extensively\",\n      \"pmids\": [\"11967537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human AGPAT2 and AGPAT1 show similar in vitro substrate specificities for LPA and acyl-CoA; both co-localize to the endoplasmic reticulum when co-expressed; protein homology modeling with GPAT1 reveals similar tertiary structure consistent with substrate specificity.\",\n      \"method\": \"In vitro enzymatic assays with LPA and acyl-CoA substrates, co-localization by fluorescence microscopy, protein homology modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assay with substrate specificity profiling, structural modeling, direct localization by co-expression imaging, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21873652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Restoring AGPAT2 activity specifically in the liver by adenoviral overexpression of AGPAT1 or AGPAT2 in Agpat2-/- mice failed to ameliorate hepatic steatosis, indicating that liver-specific AGPAT activity is not the primary driver of hepatic fat accumulation in lipodystrophy.\",\n      \"method\": \"Adenoviral gene delivery to liver of Agpat2-/- mice followed by measurement of liver triglycerides\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean in vivo genetic rescue experiment, single lab, negative finding is mechanistically informative\",\n      \"pmids\": [\"21873652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In Agpat2-/- mice, hepatic de novo fatty acid biosynthesis is increased ~4-fold and monoacylglycerol acyltransferase isoform 1 (MOGAT1) mRNA and protein are markedly upregulated, indicating activation of an alternative monoacylglycerol pathway for triglyceride biosynthesis to compensate for AGPAT2 deficiency.\",\n      \"method\": \"Agpat2 knockout mouse model; de novo lipogenesis rates measured; mRNA and protein analysis of MOGAT1; fat-free diet intervention\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (metabolic flux, gene/protein expression, dietary intervention) in a clean KO model, single lab with rigorous controls\",\n      \"pmids\": [\"19187773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Seipin oligomers (dodecamers) can directly interact with AGPAT2 during adipogenesis, and a single seipin complex can simultaneously bind both AGPAT2 and lipin 1, physically scaffolding these two sequential enzymes of the PA biosynthesis pathway; stabilizing the seipin-AGPAT2 interaction increases nuclear accumulation of PPARγ.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, atomic force microscopy (AFM) to determine direct protein-protein interaction and molecular architecture\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct interaction confirmed by AFM reconstitution plus reciprocal Co-IP and functional consequence (PPARγ nuclear accumulation), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25737955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AGPAT2 regulates adipogenesis by modulating levels of phosphatidic acid, lysophosphatidic acid, phosphatidylinositol species, and the PPARγ inhibitor cyclic phosphatidic acid; loss of AGPAT2 activity reduces Akt activation, and constitutively active Akt partially restores lipogenesis, placing AGPAT2 upstream of PI3K/Akt and PPARγ pathways in early adipogenesis.\",\n      \"method\": \"Knockdown and overexpression of AGPAT2 in 3T3-L1 and patient-derived MDMCs; lipidomics; retroviral rescue; constitutively active Akt rescue; PPARγ agonist rescue\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including lipidomics, genetic epistasis via constitutively active Akt, and pharmacological rescue, single lab\",\n      \"pmids\": [\"22872237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Specific molecular species of phosphatidic acid (PA C16:0/18:1 and C18:1/20:4) generated in the absence of AGPAT2 enhance hepatic glucose production (HGP) in primary hepatocytes by upregulating gluconeogenic enzymes glucose-6-phosphatase and PEPCK; this PA-driven gluconeogenesis is suppressed by insulin in wild-type but not Agpat2-/- hepatocytes, establishing PA as a driver of hepatic insulin resistance.\",\n      \"method\": \"Primary hepatocyte assays with exogenous PA species; measurement of glucose production; diacylglycerol kinase and phospholipase D activity assays in Agpat2-/- liver; insulin suppression experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution with defined lipid species, biochemical assays of upstream enzymes, and functional insulin-signaling readout in KO vs WT cells, single lab, multiple methods\",\n      \"pmids\": [\"24425876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AGPAT2 directly interacts with CDP-diacylglycerol synthases (CDS1 and CDS2), forming functional complexes that promote flux of PA into the CDP-DAG phospholipid synthesis pathway; AGPAT2 deficiency destabilizes CDS proteins and reduces CDS activity, paradoxically increasing PA levels despite AGPAT2 producing PA.\",\n      \"method\": \"Co-immunoprecipitation, lipidomics, CDS activity assays in cell lines and mouse liver, knockout models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reciprocal Co-IP demonstrating direct interaction, enzyme activity assays, lipidomics, and KO models in two systems (cells and mouse liver), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34824276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"AGPAT2 deficiency causes postnatal loss of both white and brown adipose tissue through adipocyte death and local inflammation during the first postnatal week; Agpat2-/- adipocytes are virtually devoid of caveolae, have abnormal mitochondria and lipid droplets, and show 3-fold elevated phosphatidic acid in phospholipid composition; PPARγ overexpression increases differentiation but does not rescue morphological abnormalities or cell death.\",\n      \"method\": \"Light and electron microscopy of adipose tissue, phospholipid profiling by ESI-MS/MS, PPARγ overexpression rescue in MEFs, immunoblot and qPCR\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ultrastructural analysis combined with lipidomics, genetic rescue experiment, and mRNA/protein analysis in both in vivo and in vitro systems, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27408775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AGPAT2 gene expression is directly regulated by HIF-1 transcription factor; HIF-1α binds a specific HRE in the AGPAT2 promoter (confirmed by ChIP), and mutation of this HRE abolishes hypoxic activation; AGPAT2 knockdown reduces lipid droplet accumulation and cell viability under hypoxia and increases sensitivity to etoposide.\",\n      \"method\": \"siRNA knockdown of HIF-1α; reporter gene assays with AGPAT2 promoter-HRE constructs; chromatin immunoprecipitation (ChIP); HRE mutagenesis; lipid droplet quantification; cell viability assays\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP confirming direct TF binding, HRE mutagenesis abolishing activation, functional knockdown phenotype, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"29908837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Seipin and GPAT3 associate via direct interaction, and seipin can simultaneously bind GPAT3 and AGPAT2, suggesting a trimeric complex that co-ordinates sequential steps of the glycerophospholipid pathway; inhibition of AGPAT2 or GPAT3 individually impairs early adipocyte differentiation markers.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of seipin/AGPAT2/GPAT3, adipogenesis assays in cultured cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP showing direct interaction and functional KD effects on adipogenesis, but trimeric complex inferred rather than directly demonstrated, single lab\",\n      \"pmids\": [\"32094408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The p.Cys48Arg and p.Leu228Pro AGPAT2 mutations result in significantly reduced protein levels despite normal mRNA levels (post-translational destabilization); these mutants fail to rescue adipogenesis in AGPAT2-deficient preadipocytes, whereas wild-type AGPAT2 partially rescues differentiation.\",\n      \"method\": \"Expression of mutant vs wild-type AGPAT2 in AGPAT2-deficient preadipocytes; mRNA and protein quantification; adipogenesis rescue assay\",\n      \"journal\": \"JIMD reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — protein vs mRNA discordance established by direct measurement, functional rescue experiment, single lab with two orthogonal readouts\",\n      \"pmids\": [\"23430550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A double-mutant AGPAT2 protein (V67M;V167A) is enzymatically inactive as measured by in vitro mass spectrometry-based activity assay, and is associated with partial lipodystrophy when present as a single complex allele.\",\n      \"method\": \"In vitro enzymatic activity assay with mass spectrometry readout; whole genome sequencing for allele identification\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro enzymatic assay is Tier 1, but single patient case study with single lab, no independent replication\",\n      \"pmids\": [\"30319454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Adipose-tissue-specific re-expression of human AGPAT2 in Agpat2-null mice under doxycycline regulation results in partial regeneration of white and brown adipose tissue with molecular adipocyte signatures and leptin secretion; turning off AGPAT2 expression causes total loss of regenerated adipose tissue, establishing AGPAT2 as essential for adipocyte differentiation in vivo.\",\n      \"method\": \"Doxycycline-inducible adipose-specific transgene expression in Agpat2-null mice; adipose tissue mass, histology, leptin secretion measurement; ex vivo differentiation of stromal vascular fraction cells\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reversible genetic rescue with dox on/off demonstrating causal role of AGPAT2 in adipocyte differentiation, multiple functional readouts, single lab\",\n      \"pmids\": [\"37752957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AGPAT2-generated phosphatidic acid (PA) drives ER tubulation by directly interacting with and supplying PA to the dynamin-related GTPase DRP1, which subsequently tubulates the ER independently of GTP hydrolysis and oligomerization; reduction of PA by ectopic LIPIN1 expression converts ER tubules into sheets, establishing AGPAT2 as a critical regulator of ER morphogenesis.\",\n      \"method\": \"Gene knockout, 3D structural analysis by FIB-SEM, super-resolution microscopy, lipidomics, AlphaFold structural modeling, in vitro reconstitution of ER tubulation, in vitro AGPAT2 activity assay, LIPIN1 ectopic expression\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of ER tubulation, direct enzymatic assay, multiple structural methods (FIB-SEM, super-resolution), lipidomics, and genetic epistasis all in single study; multiple orthogonal methods with rigorous controls\",\n      \"pmids\": [\"41387688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"AGPAT2 localizes to nuclear pore complexes (NPCs) where it is bound and inhibited by Dop1a under mTOR signaling control to regulate phospholipid abundance in nuclear membranes; when LPA is limiting, Dop1a rapidly translocates to NPCs and suppresses AGPAT2-mediated PA synthesis, preventing formation of nuclear lipid droplets.\",\n      \"method\": \"Localization studies of AGPAT2 at NPCs, Dop1a knockout and rescue, mTOR signaling perturbation, nuclear lipid droplet quantification, nuclear membrane phospholipid measurement\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct binding and NPC localization demonstrated functionally, but single lab and limited replication; mechanistic detail of Dop1a-AGPAT2 interaction at NPCs is novel\",\n      \"pmids\": [\"42164854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"AGPAT2 inhibitor (LPAAT-β inhibitor CT-32615) triggers G2/M cell cycle arrest via downregulation of cdc25c and cdc2, and induces necrotic cell death (without caspase/PARP cleavage) even in bortezomib-resistant cells.\",\n      \"method\": \"Pharmacological inhibition of LPAAT-β/AGPAT2 with CT-32615; cell cycle analysis; caspase/PARP cleavage assays; cell viability assays in resistant cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — pharmacological inhibition with defined cell-cycle and death mechanism readouts, but relies on inhibitor specificity assumption; single lab with multiple phenotypic readouts\",\n      \"pmids\": [\"15735676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Decreased caveolae in Agpat2-/- adipocytes are not associated with changes in plasma membrane cholesterol or sphingolipid levels, nor with changes in caveolin-1 or cavin-1 protein levels; however, increased plasma membrane phosphatidylserine is detected in Agpat2-/- adipocytes at day 10 of differentiation, suggesting a possible role for this lipid in caveolae reduction.\",\n      \"method\": \"Plasma membrane purification by ultracentrifugation; sterol, sphingolipid, and phospholipid lipidomics; caveolae quantification by electron microscopy; immunoblot for caveolin-1 and cavin-1\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comprehensive lipidomics with subcellular fractionation and protein analysis, negative findings are mechanistically informative, single lab\",\n      \"pmids\": [\"33989739\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AGPAT2 is an endoplasmic reticulum-localized (and nuclear pore complex-associated) lysophosphatidic acid acyltransferase that catalyzes the conversion of LPA to phosphatidic acid (PA) in the glycerol-3-phosphate pathway; the PA it generates drives ER tubulation via direct interaction with DRP1, channels into the CDP-DAG phospholipid synthesis pathway through direct interaction with CDS1/2, and is an essential regulator of adipocyte differentiation acting upstream of PI3K/Akt and PPARγ signaling; seipin scaffolds AGPAT2 together with lipin 1 in a multiprotein complex at the ER to coordinate sequential PA metabolism steps during adipogenesis, while HIF-1α directly transactivates AGPAT2 expression under hypoxia to promote lipid droplet accumulation and cell survival.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AGPAT2 is an endoplasmic reticulum-localized 1-acylglycerol-3-phosphate O-acyltransferase that acylates lysophosphatidic acid (LPA) to phosphatidic acid (PA), a central intermediate for triacylglycerol and glycerophospholipid biosynthesis, and its loss-of-function mutations cause congenital generalized lipodystrophy [#0, #1]. The PA pool generated by AGPAT2 serves multiple downstream fates: it is channeled into the CDP-DAG phospholipid synthesis pathway through direct interaction with the CDP-diacylglycerol synthases CDS1/CDS2, whose stability and activity depend on AGPAT2 [#7], and it drives ER tubulation by supplying PA to the dynamin-related GTPase DRP1 to remodel ER membrane morphology [#14]. AGPAT2 is an essential regulator of adipocyte differentiation, acting upstream of PI3K/Akt and PPARγ signaling by tuning levels of PA, LPA, phosphatidylinositol species, and the PPARγ inhibitor cyclic PA [#5], and its activity is genetically required for adipose tissue formation and maintenance in vivo [#13]. At the ER, seipin oligomers physically scaffold AGPAT2 together with lipin 1 to coordinate sequential PA metabolism during adipogenesis [#4]. Transcriptionally, HIF-1α directly binds an HRE in the AGPAT2 promoter to induce its expression under hypoxia, promoting lipid droplet accumulation and cell survival [#9]. Misregulation of AGPAT2-derived PA has systemic metabolic consequences, including PA-species-driven hepatic glucose production and insulin resistance [#6].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the molecular identity and clinical relevance of AGPAT2 by linking its acyltransferase activity to a human disease, answering what the gene does and why its loss matters.\",\n      \"evidence\": \"Mutation identification in lipodystrophy patients combined with enzymatic function annotation\",\n      \"pmids\": [\"11967537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve subcellular site of catalysis\", \"Did not define which downstream PA pools account for the disease phenotype\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed how cells compensate for AGPAT2 loss, revealing activation of an alternative MOGAT1-dependent monoacylglycerol pathway and elevated de novo lipogenesis as a route to triglyceride synthesis.\",\n      \"evidence\": \"Agpat2 knockout mouse with metabolic flux, gene/protein expression, and dietary intervention\",\n      \"pmids\": [\"19187773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether compensation occurs in adipose or only liver\", \"Did not link compensatory pathway to lipodystrophy progression\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the biochemical substrate specificity and ER localization of AGPAT2 and showed, via liver-specific rescue failure, that hepatic AGPAT activity is not the primary driver of lipodystrophic steatosis.\",\n      \"evidence\": \"In vitro acyltransferase assays, co-localization imaging, homology modeling, and adenoviral liver rescue in knockout mice\",\n      \"pmids\": [\"21873652\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the tissue where AGPAT2 activity is essential\", \"No experimental structure of AGPAT2\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed AGPAT2 upstream of PI3K/Akt and PPARγ in adipogenesis by showing that its lipid products control these signaling pathways, and identified post-translational destabilization as a disease mechanism for specific mutants.\",\n      \"evidence\": \"Knockdown/overexpression in 3T3-L1 and patient cells, lipidomics, Akt and PPARγ rescue; mutant protein/mRNA quantification and rescue assays\",\n      \"pmids\": [\"22872237\", \"23430550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which PA/LPA species mediate each signaling step\", \"Mechanism connecting lipid changes to Akt activation not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected AGPAT2-related lipid dysregulation to systemic insulin resistance by showing that specific PA species accumulating in its absence drive hepatic glucose production resistant to insulin suppression.\",\n      \"evidence\": \"Primary hepatocyte assays with defined PA species, gluconeogenic enzyme measurement, and insulin suppression in KO vs WT\",\n      \"pmids\": [\"24425876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the PA receptor/sensor driving gluconeogenesis\", \"Did not separate liver-autonomous from systemic effects\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed how AGPAT2 is spatially organized for adipogenesis, demonstrating that seipin scaffolds AGPAT2 and lipin 1 into a complex that coordinates sequential PA metabolism and promotes PPARγ nuclear accumulation.\",\n      \"evidence\": \"Co-immunoprecipitation, immunofluorescence, and atomic force microscopy\",\n      \"pmids\": [\"25737955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the in vivo complex not resolved\", \"Did not show PA channeling within the complex directly\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Characterized the cellular and ultrastructural basis of adipose loss in AGPAT2 deficiency, showing postnatal adipocyte death, absent caveolae, abnormal organelles, and elevated PA that PPARγ overexpression cannot rescue.\",\n      \"evidence\": \"Electron microscopy, phospholipid profiling by ESI-MS/MS, and PPARγ rescue in MEFs\",\n      \"pmids\": [\"27408775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking PA elevation to adipocyte death unresolved\", \"Cause of caveolae loss not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified hypoxia-driven transcriptional control of AGPAT2 by HIF-1α and tied this to lipid droplet accumulation and survival, expanding AGPAT2's role beyond adipogenesis into stress responses.\",\n      \"evidence\": \"HIF-1α knockdown, AGPAT2 promoter-HRE reporters, ChIP, HRE mutagenesis, lipid droplet and viability assays\",\n      \"pmids\": [\"29908837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish tissue contexts where this axis operates\", \"Did not link HIF-driven AGPAT2 to tumor lipid metabolism in vivo\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided direct enzymatic evidence that compound missense mutations abolish AGPAT2 catalytic activity and associate with partial lipodystrophy, refining genotype-function correlation.\",\n      \"evidence\": \"In vitro mass spectrometry activity assay and whole genome sequencing in a patient case\",\n      \"pmids\": [\"30319454\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single patient case without independent replication\", \"Did not separate contributions of each mutation\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended the seipin scaffolding model upstream by showing seipin can also bind GPAT3 and simultaneously engage AGPAT2, implying a trimeric platform for sequential glycerophospholipid synthesis in adipogenesis.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, and adipogenesis assays in cultured cells\",\n      \"pmids\": [\"32094408\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trimeric complex inferred rather than directly demonstrated\", \"Stoichiometry and assembly order not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the paradox of PA accumulation in AGPAT2 deficiency by showing AGPAT2 directly binds and stabilizes CDS1/CDS2 to channel PA into the CDP-DAG pathway, so its loss collapses downstream PA consumption.\",\n      \"evidence\": \"Reciprocal Co-IP, lipidomics, CDS activity assays, and knockout models in cells and mouse liver\",\n      \"pmids\": [\"34824276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of AGPAT2-CDS interaction not determined\", \"Did not quantify substrate channeling kinetics\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Dissected the caveolae defect in AGPAT2-null adipocytes, excluding cholesterol, sphingolipid, and caveolin/cavin protein changes and implicating elevated plasma membrane phosphatidylserine.\",\n      \"evidence\": \"Plasma membrane fractionation, lipidomics, electron microscopy, and immunoblotting\",\n      \"pmids\": [\"33989739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role of phosphatidylserine in caveolae loss not proven\", \"Did not connect caveolae loss to adipocyte function\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established AGPAT2 as causally required for adipocyte differentiation in vivo through reversible adipose-specific re-expression that regenerates adipose tissue and is lost when expression is switched off.\",\n      \"evidence\": \"Doxycycline-inducible adipose-specific transgene in Agpat2-null mice with histology, leptin, and ex vivo differentiation\",\n      \"pmids\": [\"37752957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the minimal AGPAT2-dependent lipid signal for differentiation\", \"Partial regeneration mechanism not fully defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Uncovered a structural role for AGPAT2-generated PA in organelle morphogenesis, showing PA is supplied to DRP1 to drive ER tubulation independently of DRP1 GTP hydrolysis, with PA reduction converting tubules into sheets.\",\n      \"evidence\": \"Knockout, FIB-SEM, super-resolution microscopy, lipidomics, AlphaFold modeling, in vitro ER tubulation reconstitution and activity assays, LIPIN1 expression\",\n      \"pmids\": [\"41387688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how local PA pools are spatially restricted at ER tubules\", \"Physiological consequences of altered ER morphology in lipodystrophy not assessed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed a nuclear pore complex pool of AGPAT2 under mTOR/Dop1a control that gates nuclear membrane phospholipid synthesis and prevents nuclear lipid droplet formation when LPA is limiting.\",\n      \"evidence\": \"NPC localization studies, Dop1a knockout/rescue, mTOR perturbation, and nuclear lipid droplet and phospholipid measurements\",\n      \"pmids\": [\"42164854\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab with limited replication of NPC localization\", \"Molecular details of Dop1a-AGPAT2 inhibition not structurally defined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrated that pharmacological AGPAT2/LPAAT-β inhibition imposes G2/M arrest and caspase-independent necrotic death, including in bortezomib-resistant cells, indicating a role in cell cycle and survival exploitable therapeutically.\",\n      \"evidence\": \"CT-32615 inhibition with cell cycle analysis, caspase/PARP assays, and viability in resistant lines\",\n      \"pmids\": [\"15735676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relies on inhibitor specificity for AGPAT2\", \"Mechanism linking AGPAT2 activity to cdc25c/cdc2 downregulation not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AGPAT2-generated PA is spatially partitioned among its distinct fates — CDS-mediated phospholipid synthesis, DRP1-driven ER tubulation, signaling pools regulating adipogenesis, and nuclear membrane biogenesis — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental structure of AGPAT2 or its protein complexes\", \"No mechanism explaining selective channeling of PA into competing downstream pathways\", \"Tissue-specific regulation of the distinct AGPAT2 functions undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 12, 14]},\n      {\"term_id\": \"GO:0016746\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 14]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0008654\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 6, 7]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 13]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"complexes\": [\n      \"seipin–AGPAT2–lipin 1 scaffold complex\",\n      \"AGPAT2–CDS1/CDS2 complex\"\n    ],\n    \"partners\": [\n      \"BSCL2\",\n      \"LPIN1\",\n      \"CDS1\",\n      \"CDS2\",\n      \"GPAT3\",\n      \"DRP1\",\n      \"DOP1A\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}